Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the third leading cause of cancer mortality worldwide [1,2]. HCC prognosis remains poor, partly because up to 70% of patients are diagnosed with advanced HCC at initial presentation, precluding curative treatments such as resection, liver transplantation (LT) or ablation [3]. Survival outcomes for HCC are better among patients who receive curative rather than non-curative therapies [4]. There is therefore a need to optimize treatment for the majority of patients who undergo non-curative therapy.

Source: Cancer Treatment Reviews - March 1, 2023 Category: Cancer & Oncology Authors: Jason K Wong, Howard J Lim, Vincent C Tam, Kelly W Burak, Laura A Dawson, Prosanto Chaudhury, Robert J Abraham, Brandon M Meyers, Gonzalo Sapisochin, David Valenti, Setareh Samimi, Ravi Ramjeesingh, Amol Mujoomdar, Ilidio Martins, Elijah Dixon, Maja Seged Tags: Anti-tumour Treatment Source Type: research